# Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

> **NCT00379483** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Transfusional Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00379483
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2015-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379483, "Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload". Retrieved via MORVS 2026-10-28 from https://api.morvs.ai/clinical/NCT00379483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*